 CAMBRIDGE, Mass., Oct. 12, 2021 GLOBE NEWSWIRE -- Vor Biopharma Nasdaq: VOR, a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vors Senior Vice President of Program and Alliance Management. Dr. Schmelmer has more than 25 years of experience leading the development of novel therapies for cancer, autoimmune disorders and infectious diseases at leading biopharmaceutical companies. 